H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $5 from $7 and keeps a Buy rating on the shares. The firm reduced sales forecasts for BXCL501 with the company’s strategic reprioritization focusing on clinical development and ablated commercial infrastructure.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics announces DOD grant to UNC to fund study of BXCL501
- Bioxcel Therapeutics Senior VP Wiley Transitions to Consultant
- Bioxcel Therapeutics Announces Restructuring and Leadership Changes
- BioXcel announces clinical prioritization of late-stage BXCL501 programs
- BioXcel Therapeutics announces initiation of SERENITY Phase 3 trial